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Background
Western Australia recently hosted Australia’s inaugural
national rare diseases symposium, entitled Awakening
Australia to Rare Diseases: Global perspectives on
establishing a coordinated approach to a national
plan http://www.raredisease.com.au in the port city of
Fremantle, Western Australia from the 17th-20th of
April 2011.
The Office of Population Health Genomics (OPHG),
Department of Health Western Australia, in conjunction
with the Australian Paediatric Surveillance Unit (APSU),
initiated the Symposium and established National and
Local Organizing Committees to compose a program that
included plenary sessions of invited speakers followed by
small group discussions to explore issues raised in the for-
mal presentations. The sessions and content were
informed by the Western Australian supporting organisa-
tion branches of Carers Australia, Cystic Fibrosis Australia,
Motor Neurone Disease Australia, Multiple Sclerosis
Society of Western Australia, Muscular Dystrophy WA
and Senses Foundation with clinical and disability insights
from Genetic Services of Western Australia and the Dis-
ability Services Commission. This national rare disease
symposium built on the work begun by the Human
Genetics Society of Australasia (HGSA) on rare genetic
disorders and more recently by the ASPU led Rare Dis-
eases Working Group [1].
International speakers and advisors presented their
experiences and perspectives as representatives of a
range of organisations and institutions including the U.S.
National Organisation for Rare Disorders (NORD), the
International Conferences on Rare Diseases (ICORD),
New Zealand Organisation for Rare Diseases (NZORD),
European Organisation on Rare Diseases (EURORDIS),
Orphanet and the U.S. National Institutes of Health
Office of Rare Diseases Research. More than 160 speakers
and delegates attended from a range of countries includ-
ing Australia, North America, United Kingdom, New
Zealand, France, Hong Kong and Singapore. The major-
ity of delegates were people living with a rare disease
who generously shared their personal narratives and con-
tributed invaluable information on many of the issues
that will lead to the formulation of a National Plan.
Key Outcomes
The Symposium registration session included the launch
of “Rare Friends”, a non-partisan network of State politi-
cians, formed to raise awareness of the impact of rare dis-
orders in the community and to support solutions that
improve life outcomes for those living with rare disorders
http://www.raredisease.com.au. In addition, Rare Friends
are committed to extending their network through State
and Federal parliamentary colleagues.
Dr Noel Nannup, a respected indigenous Noongar Elder
and scholar, provided a stirring welcome to country in the
Noongar language and a translation and explanation of
the ceremony with reference to the gathering of delegates
at the Symposium. Mr Kim Snowball, Director General of
the Department of Health in Western Australia then
launched the Symposium by highlighting the importance
of rare diseases within the context of health service deliv-
ery [2,3]. He spoke of the impact of chronic, often life-
shortening and generally debilitating diseases and the
frequent associations with other co-morbidities such as
developmental delays, depression and intellectual disability
[4-6]. According to best estimates rare diseases cumula-
tively affect between 6-8% of the Australian population
[1,4,7]. Mr Snowball observed that the issues confronting
those with rare diseases are universal and are best
researched and addressed through global collaborations.
He announced that this Symposium was the starting point
for a Western Australian rare disease plan that will feed
into a national rare disease strategy [8-12]. Mr Snowball
committed WA Health to working with health profes-
sionals, service providers and governments to improve the
health and well being of people with rare diseases.
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Over the three days of the Symposium program the
delegates had the opportunity to listen to the vast experi-
ences of the international speakers and, more importantly,
people living with rare diseases. (Refer to full program
http://www.raredisease.com.au). These talks covered a
wide range of policy issues including participant and pro-
fessional perspectives of the history of a national plan in
Australia, the role of umbrella organisations (NORD: The
National Organization for Rare Disorders in the United
States of America and EURORDIS: Rare Diseases Europe),
the roles of general practitioners, specialist physicians and
disability services, clinical trials and registries, and the
effective application of coordinated networks to advocate
on behalf of those with rare diseases. Several individuals
shared their personal experiences of diagnosis, therapeutic
interventions and prognoses. Among the most poignant
was the story of a young man with a progressive neuro-
muscular disorder, who began by asking the delegates not
to focus on his genetic diagnosis as he was one of many
who lived with some form of rare disease. His final mes-
sage, “I don’t need to be cured, I just want to live” encap-
sulated the need to accommodate multidimensional
themes in a rare disease strategy.
Collectively the plenary talks were crucial in framing the
stakeholder engagement workshop sessions which were
conducted as deliberative-style discussions [13]. During
these sessions, participants discussed their perspectives on
the goals of a national plan, empowerment and advocacy,
medical and social support agencies, research and transla-
tion, networks and partnerships that led to a consensus on
recommending the development of a national plan for
rare diseases. At the end of each workshop session each
group prepared a written summary of their deliberations
and outcomes which were collated for review.
Preliminary analyses of participant responses to an end-
of-forum survey indicate satisfaction that the engagement
process was transparent, respectful and very useful to
identify the key issues for the rare diseases community.
Participants also reflected that it was important to estab-
lish a cooperation network that created a single voice on
behalf of those with rare diseases in Australia.
Although the feedback is still being analysed, there
was consensus on key issues:
■ An enthusiastic endorsement to develop a
National Plan informed by the symposium work-
shops and ongoing engagement processes, building
on existing international frameworks and national
plans such as the EUROPLAN and to facilitate inter-
national collaborations;
■ The agreement to form a single overarching advo-
cacy group for rare diseases in Australia that ensures
a voice for all persons living with a rare disease;
■ A recognition that advocacy to government on
behalf of all rare diseases requires collaboration with
the pharmaceutical industry and academic research-
ers to drive developments;
■ Agreement on the need for improvements in the
collection and analyses of the incidence and preva-
lence of rare diseases, the costs to families, commu-
nity, national productivity, and the health and
disability services through voluntary national rare
disease registries;
■ Specific attention was directed towards exploring
how service delivery could be improved through
integrated, multi-disciplinary clinical and support
networks with shared care, management and services
requirements and support for the proposed National
Disability Insurance Scheme http://www.everyaustra-
liancounts.com.au.
Conclusion
The meeting concluded with an open session and a discus-
sion of delegates’ views about the actions that would
advance the development of the National Plan. The Direc-
tor of OPHG, Dr Peter O’Leary summarised the successful
outcomes of the deliberative engagement sessions, noting
the five themes (above) that will be carried forward with
the enthusiastic endorsement of all the delegates.
As a farewell message, we were reminded that Dr
Nannup had provided each delegate with the gift of a tra-
ditional Indigenous message stick to commemorate the
gathering, the discussions and the shared decisions to go
forward. These sticks serve as symbols of the communal
responsibility to maintain the spirit of collaboration, com-
munication and goodwill shared at the Symposium.
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